BRISTOL-MYERS SQUIBB COMPANY Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) of -$85.00 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-12.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements · last filed 2016-02-12
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for fiscal 2015 was -$85.00M.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for fiscal 2014 was -$103.00M.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for fiscal 2013 was -$118.00M.
- BRISTOL-MYERS SQUIBB COMPANY fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, purchases, (sales), issuances, (settlements) for fiscal 2010 was -$93.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases, (Sales), Issuances, (Settlements) 12 month |
|---|---|
| 2015-12-31 | -$85.00M 10-K · filed 2016-02-12 |
| 2014-12-31 | -$103.00M 10-K · filed 2016-02-12 |
| 2013-12-31 | -$118.00M 10-K · filed 2015-02-13 |
| 2010-12-31 | -$93.00M 10-K · filed 2011-02-18 |
| 2009-12-31 | -$155.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |